Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Essential Therapeutics (ETRX) formerly Microcide (MCDE -- Ignore unavailable to you. Want to Upgrade?

To: SemiBull who wrote (396)	8/11/2002 8:43:06 PM
From: SemiBull	Read Replies (1) \| Respond to of 415

Essential Therapeutics Enters Collaborative Agreement With Fujisawa Pharmaceutical Co., Ltd. WALTHAM, Mass., Aug. 9 /PRNewswire/ -- Essential Therapeutics, Inc. (Nasdaq: ETRX - News), today announced that it has entered into a collaborative agreement with Fujisawa Pharmaceutical Co., Ltd. Under the agreement, Essential Therapeutics will utilize its technology to develop assay systems for the discovery of novel antibiotics, and will perform high-throughput screening of the compounds in Fujisawa's library through its subcontractor. Fujisawa will conduct lead generation and lead optimization, and will exclusively develop, manufacture and market the resulting products on a worldwide basis. Essential will retain rights to develop the compounds under certain conditions and will receive funding and potential milestone and royalty payments. About Essential Therapeutics Essential Therapeutics, Inc. is committed to the development of breakthrough biopharmaceutical products for the treatment of life-threatening diseases. With an emerging pipeline of lead programs and product candidates in the anti-infective and hematology/oncology therapy areas, Essential Therapeutics is dedicated to commercializing novel small molecule products addressing important unmet therapeutic needs. Additional information on Essential Therapeutics can be obtained at essentialtherapeutics.com . Statements contained herein that are not historical fact may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements made by Essential Therapeutics. These factors include, but are not limited to, Essential Therapeutics' ability to: (i) develop assay systems for novel antibiotics; (ii) develop breakthrough pharmaceutical products; and (iii) our partner's ability to successfully take discovered compounds through pre-clinical development, clinical trials and commercialization. For a discussion of other risks and uncertainties affecting Essential Therapeutics' business, see the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2002. Actual results and timing of certain events could differ materially from those indicated in the forward-looking statements as a result of these or other factors. SOURCE: Essential Therapeutics, Inc.